Onivyde and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Onivyde (irinotecan hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Fluorouracil, and have Pancreatic carcinoma metastatic.

The phase IV clinical study analyzes which people have Disease progression when taking Onivyde. It is created by eHealthMe based on reports of 1,198 people who have side effects when taking Onivyde from the FDA, and is updated regularly.

What is Onivyde?

Onivyde has active ingredients of irinotecan hydrochloride. eHealthMe is studying from 1,198 Onivyde users. Check the latest studies of Onivyde.

What is Disease progression?

Disease progression is found to be associated with 1,797 drugs and 2,257 conditions by eHealthMe. Check the latest studies of Disease progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

1,198 people reported to have side effects when taking Onivyde.
Among them, 93 people (7.76%) have Disease progression.

Could Onivyde cause Disease progression?

Among these 93 people:

How long have people been on Onivyde when they have Disease progression? *

What is the gender of people who have Disease progression when taking Onivyde? *

female: 48.48 %
male: 51.52 %

What is the age of people who have Disease progression when taking Onivyde? *

What are other drugs people take besides Onivyde? *

Fluorouracil: 20 people, 21.51%
Gemcitabine: 18 people, 19.35%
Ondansetron: 18 people, 19.35%
Ifosfamide: 13 people, 13.98%
Cyclophosphamide: 13 people, 13.98%
Docetaxel: 13 people, 13.98%
Topotecan: 13 people, 13.98%
Temozolomide: 13 people, 13.98%
Melatonin: 13 people, 13.98%
Doxorubicin Hydrochloride: 12 people, 12.90%

What are other side effects people have besides Disease progression? *

Ascites (accumulation of fluid in the abdominal cavity): 13 people, 13.98%
Metastases To Liver (cancer spreads to liver): 13 people, 13.98%
Diarrhea: 13 people, 13.98%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 12 people, 12.90%
Malignant Neoplasm Progression (cancer tumour came back): 12 people, 12.90%
Fatigue (feeling of tiredness): 10 people, 10.75%
Weakness: 10 people, 10.75%
Metastases To Lymph Nodes (cancer spreads to lymph node): 10 people, 10.75%
Desmoplastic Small Round Cell Tumor: 10 people, 10.75%
Metastases To Peritoneum (cancer spreads to peritoneum): 9 people, 9.68%

What are the existing conditions these people have? *

Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 20 people, 21.51%
Pancreatic Carcinoma (pancreatic cancer): 19 people, 20.43%
Malignant Neoplasm Progression (cancer tumour came back): 13 people, 13.98%
Desmoplastic Small Round Cell Tumor: 13 people, 13.98%
Adenocarcinoma Pancreas (cancer of pancreas): 9 people, 9.68%
Metastases To Liver (cancer spreads to liver): 3 people, 3.23%
Pain: 3 people, 3.23%
Diarrhea: 2 people, 2.15%
Nausea (feeling of having an urge to vomit): 2 people, 2.15%
Oedema (fluid collection in tissue): 1 person, 1.08%

* Approximation only. Some reports may have incomplete information.

Do you take Onivyde and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Onivyde:

Onivyde (1,198 reports)

Browse all side effects of Onivyde:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,797 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,257 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on irinotecan hydrochloride (the active ingredients of Onivyde) and Onivyde (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.